Establishment of a Reliable Method for Detecting the Residual HEK293 Host Cell Protein in Recombinant Adeno-Associated Virus Vector
QU Wei-hong1,2,3, XU Rui-an1,3,*
1.School of Medicine and Institute of Molecular Medicine, Huaqiao University, Quanzhou 362021, China; 2.College of Medicine and Life Science, Jiujiang University, Jiujiang 332000, China; 3.Engineering Research Centree of Molecular Medicine, Ministry of Education, Quanzhou 362021, China
Abstract��OBJECTIVE To develop a reliable method to measure host cell protein(HCP)content of HEK293 cells in rAAV2-KAL vectors for clinic application. METHODS The rAAV2-KAL vectors used for this study was purified by CsCl ultracentrifugation twice,then were subjected to by Western blot. The optimal linear range, minimum detection limit,and the accuracy and precision were verified by ELISA. Three batches of rAAV2-KAL were prepared by CsCl method. The change of HCP content during purification was determined to verify the method suitability and reliabilities. RESULTS The optimal linear range of the method developed was 4-200 ng��mL-1,while the minimum detection limit of 4 ng��mL-1. The recovery rates of HEK293 cell protein at various concentrations were at range of 77.0%-115.0%,with a coefficient of variation of less than 20%. The HCP contents in three batches of rAAV2-KAL were less than 100 ng��mL-1, all data taken together indicated that HCP was effectively removed by CsCl ultracentrifugation. CONCLUSION A reliable ELISA assay for residual host cell protein of HEK293 cells is successfully developed,which might be used for determination of HCP content in CsCl ultracentrifugation purified rAAV2-KAL for clinical application.
��ΰ��,����. ��������ز��������в���HEK293ϸ����������ⷽ���Ľ���[J]. �й�ҩѧ��־, 2016, 51(1): 52-55.
QU Wei-hong, XU Rui-an. Establishment of a Reliable Method for Detecting the Residual HEK293 Host Cell Protein in Recombinant Adeno-Associated Virus Vector. Chinese Pharmaceutical Journal, 2016, 51(1): 52-55.
GARDNER M R, KATTENHORN L M, KONDUR H R, et al. AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature, 2015, 519 (7541): 87-91.
[2]
LISOWSKI L, DANE A P, CHU K, et al. Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature, 2014, 506 (7488): 382-386.
[3]
XU R. Adeno-Associated Virus-from the Virus to Clinic (����ز���-�Ӳ������ٴ�). Beijing:Science Press. 2014:1-10.
[4]
WATANABE N, YANO K, TSUYUKI K, et al. Re-examination of regulatory opinions in Europe: Possible contribution for the approval of the first gene therapy product Glybera. Mol Ther Methods Clin Dev, 2015, 2: 14066.
[5]
WRIGHT J F, LE T, PRADO J, et al. Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulation. Mol Ther, 2005, 12 (1): 171-178.
[6]
WRIGHT J F, LE T, PRADO J, et al. Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulation. Molecular Therapy, 2005, 12 (1): 171-178.
[7]
WRIGHT J F, ZELENAIA O. Vector characterization methods for quality control testing of recombinant adeno-associated viruses. Methods Mol Biol, 2011, 737: 247-278.
[8]
WANG H X, LU G C, ZHANG Z T, et al. Technical considerations on the study and evaluation of the biosimilars immunogenicity. Chin Pharm J (�й�ҩѧ��־), 2015, 50 (6): 483-489.
[9]
ALLAY J A, SLEEP S, LONG S, et al. Good manufacturing practice production of self-complementary serotype 8 adeno-associated viral vector for a hemophilia B clinical trial. Hum Gene Ther, 2011, 22 (5): 595-604.
[10]
WANG J.The Development of Biotech Drugs and Quality Control(���\��ҩ���о���������������). Beijing: Science Press. 2007:872-882.
[11]
GAO K T L, WANG J Z. Quality control for recombinant therapeutic antibodies. Chin New Drug J (�й���ҩ��־), 2011, 20 (19): 1848-1855.
[12]
WRIGHT J F. Manufacturing and characterizing AAV-based vectors for use in clinical studies. Gene Therapy, 2008,15 (11):840-848.